Protalix Biotherapeutics Hits New 52-Week High of $3.19

Protalix Biotherapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 3.19 on February 23, 2026. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, particularly noteworthy given its microcap status with a market capitalization of USD 246 million. Over the past year, Protalix Biotherapeutics has demonstrated impressive growth, with a remarkable 163.87% increase in stock price, significantly outperforming the S&P 500, which saw a gain of only 12.95% during the same period. The company's price-to-earnings (P/E) ratio stands at 27.00, reflecting its valuation in the market, while its return on equity is reported at 10.20%, indicating effective management of shareholder equity. Additionally, Protalix maintains a price-to-book ratio of 4.65, and its debt-to-equity ratio is at -0.53, suggesting a unique financial structure. With no dividend yield currently offered, the focus remains on the company's growth trajectory and market positioning within the competitive landscape of the pharmaceuticals and biotechnology industry.